VIZZ Aceclidine: Clinical Review of the New FDA-Approved Presbyopia Drop

On 2025-07, the U.S. Food and Drug Administration (FDA) approved VIZZ aceclidine ophthalmic solution 1.44%, a first-in-class topical therapy for presbyopia [1]. Developed by LENZ Therapeutics, Inc., VIZZ is a novel cholinergic muscarinic agonist that offers a non-surgical, pharmacological approach…